Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Diffregen

Diffregen
2011 FOUNDED
PRIVATE STATUS
Accelerator/Inc LATEST DEAL TYPE
3 INVESTORS
Description

Developer of therapeutics designed to stop the progression of cancer and activate the healthy immune system. The company's services uses active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells, enabling AML patients to get proper treatement against cancer.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare
Primary Office
  • 440 Coldstream Drive
  • PA 19312
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Diffregen’s full profile, request a free trial.

Diffregen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 21-Feb-2018 Completed Startup
2. Grant 01-Jan-2013 00000 Completed Startup
1. Grant 01-Jan-2011 $100K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Diffregen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
MassChallenge Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Science Center Accelerator/Incubator 000 0000 000000 0

Diffregen Executive Team (2)

Name Title Board
Seat
Contact
Info
Deni Zodda Chief Executive Officer
George Tuszynski Ph.D Founder